Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Ho · SciRah

Researcher profile · Semantic Scholar

P. Ho

Share profile

P. Ho — researcher profile on SciRah

h-index: 23
Works: 57
Citations: 2,190

Most-cited papers

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Antoine Italiano, J. Soria, M. Toulmonde, J. Michot +16 more
2018The Lancet Oncology510 citations
Semantic Scholar
Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
S. Hirschfeld, P. Ho, Malcolm A. Smith, R. Pazdur
2003Journal of Clinical Oncology218 citations
Semantic Scholar
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
Elayne Chan-Penebre, Kelli A. Armstrong, Allison E. Drew, A. Grassian +11 more
2017Molecular Cancer Therapeutics150 citations Open access
Semantic Scholar
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
A. Storniolo, M. Pegram, B. Overmoyer, P. Silverman +11 more
2008Journal of Clinical Oncology125 citations Open access
Semantic Scholar
Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital.
P. Ho, J. Estroff, H. Kozakewich, R. Shamberger +3 more
1993Pediatrics97 citations
Semantic Scholar
Conduct of phase I trials in children with cancer.
M. Smith, M. Bernstein, W. Bleyer, J. Borsi +12 more
1998Journal of Clinical Oncology92 citations
Semantic Scholar
Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia
N. Shukla, C. Wetmore, Maureen M. O'Brien, L. Silverman +11 more
201675 citations
Semantic Scholar
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose
K. Holen, C. Belani, G. Wilding, S. Ramalingam +7 more
2010Cancer Chemotherapy and Pharmacology75 citations Open access
Semantic Scholar
Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors
H. Hurwitz, A. Dowlati, S. Savage, N. Fernando +6 more
200572 citations
Semantic Scholar
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
Howard A. Iii Burris, S. Jones, Daphne Williams, S. Kathman +5 more
2011Investigational new drugs63 citations
Semantic Scholar
INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS
F. Morschhauser, G. Salles, P. McKay, H. Tilly +22 more
201761 citations Open access
Semantic Scholar
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Q. Chu, G. Schwartz, J. de Bono, Deborah A. Smith +8 more
2007Journal of Clinical Oncology61 citations
Semantic Scholar
A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition
E. Stein, G. Garcia-Manero, D. Rizzieri, R. Tibes +15 more
201552 citations
Semantic Scholar
Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients
V. Ribrag, J. Soria, J. Michot, A. Schmitt +11 more
201545 citations
Semantic Scholar
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.
P. Schőffski, B. Cho, A. Italiano, H. Loong +12 more
202140 citations
Semantic Scholar
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).
P. Schöffski, M. Agulnik, S. Stacchiotti, Lara E. Davis +12 more
201740 citations
Semantic Scholar
Cancer recurrences and second primary cancers after use of antihistamines or antidepressants
Sheila R. Weiss, B. Mcfarland, Greg A. Burkhart, P. Ho
1998Clinical pharmacology and therapy34 citations
Semantic Scholar
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).
M. Gounder, S. Stacchiotti, P. Schöffski, S. Attia +11 more
201730 citations
Semantic Scholar
A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients
Q. Chu, L. Goldstein, N. Murray, E. Rowinsky +6 more
200530 citations
Semantic Scholar
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.
M. Agulnik, N. Tannir, J. Pressey, M. Gounder +9 more
201629 citations
Semantic Scholar
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
P. Schőffski, P. Aftimos, C. Massard, A. Italiano +4 more
2019Journal of Clinical Oncology26 citations
Semantic Scholar
Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors.
G. Schwartz, Q. Chu, L. Hammond, M. Mita +6 more
2004Journal of Clinical Oncology26 citations
Semantic Scholar
A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently.
M. Dejonge, S. Savage, J. Verweij, T. S. Collins +6 more
2006Journal of Clinical Oncology24 citations
Semantic Scholar
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
A. Pearson, K. Stegmaier, F. Bourdeaut, G. Reaman +34 more
2020European Journal of Cancer22 citations Open access
Semantic Scholar
Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies
J. Murren, G. Pizzorno, S. Distasio, A. McKeon +8 more
2002Cancer Biology & Therapy20 citations Open access
Semantic Scholar
A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects
Azra Hussaini, Rajat Mukherjee, Dina Berdieva, C. Glogowski +2 more
2019Clinical and Translational Science18 citations Open access
Semantic Scholar
302 A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors
Antoine Italiano, H. Keilhack, M. Toulmonde, J. Coindre +10 more
201516 citations
Semantic Scholar
Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition
N. Shukla, Maureen M. O'Brien, L. Silverman, M. Pauly +14 more
201515 citations Open access
Semantic Scholar
A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.
S. Chi, G. McCowage, L. Hoffman, M. Macy +7 more
201613 citations
Semantic Scholar
Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
F. Morschhauser, G. Salles, S. le Gouill, J. Radford +10 more
201612 citations
Semantic Scholar
Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI)
Malcolm A. Smith, P. Ho
2004Investigational new drugs12 citations
Semantic Scholar
Abstract A175: Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma
S. Chi, M. Fouladi, N. Shukla, F. Bourdeaut +18 more
201811 citations
Semantic Scholar
The value of label recommendations: how to dose lapatinib.
K. Koch, A. Beelen, P. Ho, D. Roychowdhury
2007Journal of Clinical Oncology11 citations
Semantic Scholar
A Phase I Study To Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Oral Platelet Growth Factor (SB-559448) in Healthy Subjects.
Sheng-Fang Su, B. Peng, Daphne Williams, J. Park +3 more
200610 citations
Semantic Scholar
Abstract 2199: BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development
Mitchell Keegan, K. Wilcoxen, P. Ho
2019Experimental and Molecular Therapeutics9 citations
Semantic Scholar
Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment
S. Daigle, A. Mcdonald, F. Morschhauser, G. Salles +23 more
20178 citations
Semantic Scholar
Phase I study of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions every 28 days in patients with solid tumors
M. Robertson, J. Kirkwood, T. Logan, H. Blair +6 more
20058 citations
Semantic Scholar
Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors.
W. Lakhai, J. Beijnen, S. Den Boer, A. Westermann +6 more
2004Journal of Clinical Oncology7 citations
Semantic Scholar
The Role of Imaging in the Development of Oncologic Agents
Anthony F. Shields, P. Ho, J. Grierson
1999Journal of clinical pharmacology7 citations
Semantic Scholar
Prostate cancer and antidepressants: A nationwide population-based nested case-control study.
Wei-Yu Lin, V. Chen, Wei-Che Chiu, Samantha J. Yim +4 more
2018Journal of Affective Disorders4 citations
Semantic Scholar
Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
F. Morschhauser, G. Salles, P. McKay, H. Tilly +23 more
20174 citations
Semantic Scholar
Efficacy of levomilnacipran extended release in treating major depressive disorder
Renee-Marie Ragguett, Samantha J. Yim, P. Ho, R. McIntyre
2017Expert Opinion on Pharmacotherapy3 citations
Semantic Scholar
PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA
S. Blakemore, S. Daigle, A. Mcdonald, F. Morschhauser +18 more
20172 citations Open access
Semantic Scholar
Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors
N. Rioux, H. Keilhack, B. Thomson, R. Chesworth +4 more
20152 citations
Semantic Scholar
A method for cancer treatment
A. Pandite, B. Whitehead, P. Ho, A. Suttle
20062 citations
Semantic Scholar
Chinese Anti鄄 Cancer a Ssociation
Pearl S. Huang, P. Ho, Kang Zhang
2 citations
Semantic Scholar
24 Phase 1 study in healthy volunteers to assess PK, PD safety & tolerability of BOS161721, an extended half-life anti-IL21 monoclonal antibody
X. Valencia, C. Glogowski, Azra Hussaini, R. Mountfield +1 more
2019Abstracts0 citations Open access
Semantic Scholar
Abstract 3345: Selective killing of SMARCA2- and SMARCA4-deficient tumors by inhibition of EZH2:In vitroandin vivopreclinical models
Elayne Chan-Penebre, Kelli A. Armstrong, Allison E. Drew, A. Grassian +9 more
20170 citations
Semantic Scholar
Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients
A. Mcdonald, F. Morschhauser, V. Ribrag, P. McKay +19 more
20170 citations
Semantic Scholar
Abstract CT031: The effect of food on the pharmacokinetics (pk) of tazemetostat in patients with cancer
B. Suttle, Sherri A. Smith, N. Waters, V. Ribrag +9 more
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Blakemore×16
Invite
S. Blakemore — researcher profile on SciRah
A. Clawson×12
Invite
A. Clawson — researcher profile on SciRah
S. Daigle×11
Invite
S. Daigle — researcher profile on SciRah
V. Ribrag×10
Invite
V. Ribrag — researcher profile on SciRah

×9

Invite

M. Roche — researcher profile on SciRah

Invite

B. Thomson — researcher profile on SciRah

Invite

A. Mcdonald — researcher profile on SciRah

Invite

S. Ribich — researcher profile on SciRah

Invite

L. Pandite — researcher profile on SciRah

F. Morschhauser×6

Invite

F. Morschhauser — researcher profile on SciRah

Invite

G. Salles — researcher profile on SciRah

Invite

P. McKay — researcher profile on SciRah